Enanta Pharmaceuticals Valuation
| ENTA Stock | USD 8.56 0.45 4.99% |
At this time, the firm appears to be undervalued. Enanta Pharmaceuticals shows a prevailing Real Value of $13.69 per share. The current price of the firm is $8.56. Our model computes the value of Enanta Pharmaceuticals from reviewing the firm fundamentals such as Operating Margin of (1.35) %, current valuation of 18.38 M, and Profit Margin of (1.60) % as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Enanta Pharmaceuticals' valuation include:
Price Book 1.329 | Enterprise Value 18.4 M | Enterprise Value Ebitda (0.29) | Price Sales 2.653 | Enterprise Value Revenue 0.2555 |
Undervalued
Today
Please note that Enanta Pharmaceuticals' price fluctuation is not too volatile at this time. Calculation of the real value of Enanta Pharmaceuticals is based on 3 months time horizon. Increasing Enanta Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Enanta Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Enanta Stock. However, Enanta Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 8.56 | Real 13.69 | Target 27.89 | Hype 8.86 |
The real value of Enanta Stock, also known as its intrinsic value, is the underlying worth of Enanta Pharmaceuticals Company, which is reflected in its stock price. It is based on Enanta Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Enanta Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Enanta Pharmaceuticals helps investors to forecast how Enanta stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Enanta Pharmaceuticals more accurately as focusing exclusively on Enanta Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Enanta Pharmaceuticals' intrinsic value based on its ongoing forecasts of Enanta Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Enanta Pharmaceuticals' closest peers. If more than one evaluation category is relevant for Enanta Pharmaceuticals we suggest using both methods to arrive at a better estimate.
Enanta Pharmaceuticals Cash |
|
Enanta Valuation Trend
Comparing Enanta Pharmaceuticals' enterprise value against its market capitalization is a good way to estimate the value of Enanta Pharmaceuticals uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Enanta Revenue by Product
Enanta Pharmaceuticals Total Value Analysis
Enanta Pharmaceuticals is currently anticipated to have valuation of 18.38 M with market capitalization of 190.91 M, debt of 26.51 M, and cash on hands of 253.29 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Enanta Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
18.38 M | 190.91 M | 26.51 M | 253.29 M |
Enanta Pharmaceuticals Investor Information
About 94.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.33. Some equities with similar Price to Book (P/B) outperform the market in the long run. Enanta Pharmaceuticals has Price/Earnings (P/E) ratio of 366.13. The entity recorded a loss per share of 5.45. The firm had not issued any dividends in recent years. Based on the key indicators related to Enanta Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Enanta Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Enanta Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Enanta Pharmaceuticals has an asset utilization ratio of 17.13 percent. This suggests that the Company is making $0.17 for each dollar of assets. An increasing asset utilization means that Enanta Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Enanta Pharmaceuticals Ownership Allocation
The majority of Enanta Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Enanta Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Enanta Pharmaceuticals. Please pay attention to any change in the institutional holdings of Enanta Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.Enanta Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 79.2 M. Net Loss for the year was (133.82 M) with profit before overhead, payroll, taxes, and interest of 86.16 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Enanta Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Enanta Pharmaceuticals and how it compares across the competition.
About Enanta Pharmaceuticals Valuation
The stock valuation mechanism determines Enanta Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Enanta Pharmaceuticals. We calculate exposure to Enanta Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Enanta Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 91.1 M | 104.6 M | |
| Pretax Profit Margin | (1.90) | (1.81) | |
| Operating Profit Margin | (1.99) | (1.89) | |
| Net Loss | (1.94) | (1.85) | |
| Gross Profit Margin | 0.87 | 0.78 |
Enanta Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 21 M | |
| Quarterly Earnings Growth Y O Y | -0.662 |
Enanta Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of Enanta Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Enanta we look at many different elements of the entity such as Enanta's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Enanta Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Enanta Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Enanta Pharmaceuticals' worth.Complementary Tools for Enanta Stock analysis
When running Enanta Pharmaceuticals' price analysis, check to measure Enanta Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enanta Pharmaceuticals is operating at the current time. Most of Enanta Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Enanta Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enanta Pharmaceuticals' price. Additionally, you may evaluate how the addition of Enanta Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |